Nasus Pharma Ltd.
AMEX: NSRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Dan Teleman
- Employees
- 7
- Headquarters
- Tel Aviv, Israel
- IPO year
- 2025
- Market cap
- $30.7M
- Website
- https://www.nasuspharma.com
Loading NSRX…
Loading profile data…Frequently asked questions about NSRX
What does Nasus Pharma Ltd. (NSRX) do?
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in se...
Where does NSRX trade?
Nasus Pharma Ltd. (NSRX) trades on the New York Stock Exchange Arca.
What sector is NSRX in?
Nasus Pharma Ltd. (NSRX) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Nasus Pharma Ltd.?
Dan Teleman is the chief executive officer of Nasus Pharma Ltd. (NSRX).
Where is Nasus Pharma Ltd. headquartered?
Nasus Pharma Ltd. is headquartered in Israel.
Does NSRX pay a dividend?
Nasus Pharma Ltd. (NSRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NSRX go public?
Nasus Pharma Ltd. (NSRX) completed its initial public offering in 2025.